A recent study found that measuring circulating tumor cells (CTCs) is a reliable way to predict later treatment response and survival prospects in men when metastatic prostate cancer is first diagnosed. The test may help providers to decide which patients should receive standard treatment vs who might stand to benefit from new drug trials. The research, part of a phase III clinical trial funded in part by the National Cancer Institute (NCI) of the National Institutes of Health, was published by Goldkorn. View full article link here.
